logo
First Signal of Climate Change Became Detectable 130 Years Ago

First Signal of Climate Change Became Detectable 130 Years Ago

Yahoo11 hours ago

If scientists of the 19th century could have used modern tools to study the atmosphere, they might have noticed the early warning signs of a major shift: human activities, like burning coal and wood, had already begun changing the climate.
In a recent thought experiment, a team of Earth and atmospheric scientists found that with the right equipment, we could have hypothetically detected the first stages of this shift by around 1885, just before fossil fuel-powered cars were invented.
Their results suggest that a discernible human influence on atmospheric temperature has likely existed for over 130 years.
In reality, the heat-trapping properties of carbon dioxide were only just being discovered in the mid-1800s. Emissions of this gas were rising as a result of the Industrial Revolution in Europe, and it wasn't until the 1970s that systematic scientific studies really began to reveal its role – and our hand – in modern climate change.
In their hypothetical scenario, the researchers set the assumption that scientists were capable of making accurate measurements of global atmospheric changes by 1860, equipping them with instruments as reliable as today's satellite microwave radiometers and contemporary estimates of carbon dioxide changes from ice cores and stratospheric balloons.
"We then apply a pattern-based 'fingerprint' method to disentangle human and natural effects on climate," the authors explain.
Despite the overall warming effect of greenhouse gases, climate change's early warning signal would have actually taken the form of stratospheric cooling. This is a direct radiative response to human emissions of carbon dioxide and other greenhouse gases, and human-driven ozone loss.
Greenhouse gases trap radiation from the Earth's surface in the lower layer of the atmosphere, the troposphere. These gases increase the reflective power of the next layer, the stratosphere, causing heat to bounce off it and back toward Earth.
Meanwhile, ozone depletion decreases the stratosphere's ability to absorb radiative heat. The overall effect is stratospheric cooling, while below, the troposphere starts to warm.
The stratosphere is also less affected by the fluctuating weather going on in the troposphere below, which is what makes it difficult to see long-term climate patterns from ground measurements.
"Pronounced cooling of the mid- to upper stratosphere, mainly driven by anthropogenic increases in carbon dioxide, would have been identifiable with high confidence by approximately 1885, before the advent of gas-powered cars," the authors write.
"Even if our monitoring capability in 1860 had not been global, and high-quality stratospheric temperature measurements existed for Northern Hemisphere mid-latitudes only, it still would have been feasible to detect human-caused stratospheric cooling by 1894, only 34 years after the assumed start of climate monitoring."
Unless someone invents a time machine, we'll never know if this foresight would have prevented the devastating effects of unchecked fossil fuel emissions through the 20th and 21st centuries, which we are only just beginning to feel. We've known about climate change for at least 50 years now, and we are still yet to find a way to quit our species' fossil fuel habit.
"We know with high confidence that sustainable pathways must be followed to avoid dangerous anthropogenic interference with climate. For the mid- to upper stratosphere and the troposphere, the projected future changes over the next 26 years are larger than the simulated changes over the 39-year period from 1986 to 2024," the authors conclude.
"Humanity is now at the threshold of dangerous anthropogenic interference. Our near-term choices will determine whether or not we cross that threshold."
The research was published in PNAS.
Extremely Dangerous Heat Wave Now Affecting Half of US Population
Glass Bottles Actually Contain More Microplastics, Scientists Find
Engineered E. Coli Transforms Waste Plastic Into Common Painkiller

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Could Ozempic Treat Migraines, Too? Small Study Finds Early Promise for GLP-1s
Could Ozempic Treat Migraines, Too? Small Study Finds Early Promise for GLP-1s

Gizmodo

timean hour ago

  • Gizmodo

Could Ozempic Treat Migraines, Too? Small Study Finds Early Promise for GLP-1s

Got a blinding headache? Some GLP-1 therapy could surprisingly help. A recent clinical trial has found early evidence that these popular drugs, typically used to treat obesity and type 2 diabetes, may also reduce migraine episodes. Researchers in Italy conducted the small pilot trial, which involved dozens of patients living with obesity and chronic migraine headaches. People experienced a significant drop in the number of migraine days each month upon taking liraglutide, the researchers found—even when they didn't lose weight on the drug. The results, while preliminary, indicate that GLP-1s could be a valuable add-on treatment for some people with migraines who haven't responded to other medications, the study authors say. 'Our findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity,' the researchers, based at the University of Naples Federico II, wrote in their paper, published this month in the journal Headache. A Florida Man's Migraines Turned Out to Be Literal Brainworms GLP-1s mimic a hormone important to regulating hunger and metabolism. This drug class has been around for two decades, and the latest approved iterations, semaglutide and tirzepatide, are substantially more effective at helping people lose weight and control their blood sugar than diet and exercise alone. Scientists have learned over time that the potential health benefits of GLP-1s may extend beyond weight loss alone, however. Some early studies have suggested GLP-1s can tamp down the drug-related cravings of people with substance use disorders, for instance. Chronic migraines are a complex condition, with many possible factors behind them. But one such factor is increased intracranial pressure in the head, according to the study researchers. Since past research has shown that GLP-1s can reduce this pressure, they hypothesized this drug class could be a potential migraine treatment. They tested liraglutide, an older GLP-1 drug, on 31 patients with obesity and unresponsive migraines for 12 weeks. By the study's end, people's average monthly days of migraine had dropped from around 20 days to just under 11—a nearly 50% drop. One participant even became completely free of migraines. Some people also experienced modest weight loss, but interestingly enough, their degree of weight loss wasn't correlated to the improvement in migraines they experienced. In other words, liraglutide's effect on migraines appeared to be independent of its weight loss effect. New Migraine Drug Can Even Tackle the Most Difficult Cases, Study Finds As the researchers fully acknowledge, this was just a proof-of-concept study, not meant to definitively prove anything. And there are important lingering questions left to resolve. Will newer GLP-1 drugs like semaglutide (Ozempic and Wegovy) be more effective at relieving pressure-related migraines as well, for example? But given how difficult migraines can be to remedy, even with recent drug approvals, finding a new and already tested avenue for treatment could be invaluable. More studies should validate whether intracranial pressure-reducing drugs, GLP-1s included, can be a new target for migraine relief, the researchers say. But it's a promising start.

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World's First Full-Length Single-Molecule Protein Sequencer
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World's First Full-Length Single-Molecule Protein Sequencer

Associated Press

time2 hours ago

  • Associated Press

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World's First Full-Length Single-Molecule Protein Sequencer

LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Portal Biotech, a pioneering biotechnology company headquartered in London, today announced a $35 million Series A raise, representing one of Europe's largest investments into a life sciences tools company. This significant milestone positions Portal Biotech as the leading innovator set to deliver the 'holy grail' of full-length single-molecule protein sequencing - a breakthrough never before accomplished - and promises transformative impact on drug discovery, precision medicine, and global biosecurity. The oversubscribed round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with substantial participation from existing investors SCVC, Pillar VC, 8VC, Amino Collective, and Outsized, as well as new investors We Venture Capital, British Business Bank and WS Investment Company (Wilson Sonsini's venture arm). Proteins drive virtually every biological process, so huge gaps in how we currently read proteins and measure the complexity of the proteome derail drug pipelines, cloud diagnostics, and leave biosecurity blind spots. Legacy tools like mass spectrometry shred proteins into fragments and miss critical protein modification patterns that change protein function, which costs industries billions in failed drug trials and misdiagnoses. Led by veterans of nanopore genomics, and powered by breakthroughs in nanopore biosensing from more than 10 years of academic research in the Maglia lab, Portal Biotech's nanopore-based platform technology is set to transform proteomics by delivering rapid, full-length, single-molecule protein characterisation at the point of need for a fraction of the price, empowering earlier go/no-go decisions, more reliable diagnostics, and stronger biosecurity responsiveness worldwide. 'Portal Biotech's technology offers unprecedented capabilities in protein identification and characterisation, providing unmatched detail on protein structure and modifications at the single-molecule level—on accessible desktop instruments that bring this state-of-the-art characterisation to any lab,' said Andy Heron, co-founder and CEO of Portal Biotech. 'These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing.' Portal Biotech's platform delivers the world's first technology for sequencing intact full-length proteins at the single-molecule level to completely characterise all protein mutations and modifications. Coupled with advanced AI methods, this data gives researchers a detailed view into the complexities of the proteome that traditional technologies cannot match, laying the groundwork for new foundational AI models of the dynamic proteome that will reshape our understanding of protein biology and accelerate breakthroughs throughout the life sciences. Portal Biotech's benchtop platforms are set to transform proteomics from a specialised, capital-intensive procedure into an agile, cost-efficient workflow that can be performed in any lab. Its accessible and high throughput instruments sidestep the expense and inaccessibility of traditional mass spectrometry, streaming whole-protein data directly to the bench so teams can accelerate early drug-discovery pipelines and make rapid diagnostic decisions. 'Portal Biotech's ability to characterise proteins at the molecular level onsite anywhere could help detect engineered biological threats faster and more accurately — crucial in defending against biowarfare and preparing us for the next pandemic, boosting the resilience of Allied nations for generations to come,' said Dr. Ana Bernardo-Gancedo, Senior Associate, NATO Innovation Fund. 'The scientific and commercial track record of the Portal Biotech team gives us tremendous confidence that they will play a defining role in the next era of proteomics.' With the genome decoded, Portal Biotech turns the spotlight to proteins to unlock new discoveries in medicine and biology that are still not accessible from genomics alone. 'We believe Portal Biotech is uniquely positioned to revolutionise protein analysis and sequencing in much the same way next-generation DNA sequencing revolutionised genomics,' said Dr. Rabab Nasrallah, Principal at Earlybird Venture Capital, Health Fund. Amid the global push to unlock the human proteome, this substantial funding will fast-track Portal Biotech's commercialisation roadmap, deepen collaborations with leading pharmaceutical and biotech innovators, and expand its R&D, engineering, and data-science teams. A photo accompanying this announcement is available at Contact [email protected]

Fact-checking viral claims that WHO just listed the contraceptive pill as a carcinogen
Fact-checking viral claims that WHO just listed the contraceptive pill as a carcinogen

Yahoo

time3 hours ago

  • Yahoo

Fact-checking viral claims that WHO just listed the contraceptive pill as a carcinogen

Viral claims that the World Health Organisation (WHO) has 'just classified the pill as a group one carcinogen' are flooding TikTok, the Chinese-owned social media platform. 'The pill is now classified as a level-one carcinogen. Like tobacco. Like alcohol. Like drugs,' one TikToker claims, prompting alarm among users of the platform. Others urge their followers to stop taking the pill altogether. Euroverify has investigated these claims and found that, while the WHO's specialised cancer agency does consider some types of contraception pills to be carcinogenic to humans, the reality is much more nuanced. It's not true that the WHO has 'just' classified the pill as a carcinogen, as TikTok users have claimed. In fact, the International Agency for Research on Cancer (IARC) – the WHO's French-headquartered cancer agency – has included certain contraceptive pills on its list of substances 'carcinogenic to humans' since 2005. That list, known as Group 1, includes substances where 'sufficient evidence of carcinogenicity' has been demonstrated in 'studies in which chance, bias, and confounding were ruled out with reasonable confidence". There are two main types of the hormonal contraceptive pill: the combined pill, which contains the hormones oestrogen and progestogen, and the mini pill, which contains progestogen only. Only the combined pill is included on the WHO's so-called Group 1, meaning there's sufficient evidence that it can cause cancer in humans. The mini pill is currently categorised in the IARC's Group 2B, meaning it's considered "possibly carcinogenic to humans." Several studies, however, have found that both of these pills slightly increase the risk of breast cancer in women. For example, a 2023 study by Oxford University's Cancer Epidemiology Unit found that any type of hormonal contraceptive may increase the risk of breast cancer, and estimated that use of the mini pill is associated with 'a 20-30% higher risk of breast cancer". But there is also data to suggest the contraceptive pill can reduce the risk of other types of cancer, such as endometrial, colorectal and bowel cancers. It means the relationship between cancer and the contraceptive pill is much more complex than meets the eye. We detected several TikTok videos published in recent weeks claiming that the WHO considers the contraceptive pill "as carcinogenic" to humans as alcohol, tobacco and asbestos. This claim is misleading. The IARC's Group 1 includes all the substances for which there is sufficient evidence of carcinogenicity in humans, such as alcohol, tobacco and asbestos, as well as processed meats, sunlight radiation and certain viruses like Hepatitis B and C. But this doesn't mean in any way that all substances on the list carry the same risk level. It simply means there is sufficient scientific evidence to support the claim that they are all carcinogenic to humans. The IARC does not classify substances according to level of carcinogenicity, but rather according to the strength of the scientific evidence to support its link to an increased risk of cancer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store